Ionis Pharmaceuticals Inc（IONS）股票分析IONSIonis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ionis Pharmaceuticals is currently not a strong buy. The stock is trading at $42.94, which is significantly below its 200-day simple moving average of $68.60, indicating a bearish trend. Additionally, the RSI is at 41.83, suggesting that the stock is nearing oversold territory but not yet a clear buy signal. The forward P/E ratio is extremely high at 90.91, indicating that the stock may be overvalued based on future earnings expectations. Furthermore, the company reported a significant year-to-date decline of 46.10%, which raises concerns about its short-term performance. The main risk is the recent negative sentiment reflected in analyst downgrades and competitive pressures, particularly from Alnylam, which reported a 41% revenue decline for Ionis compared to its own 74% growth.

15 analysts cover IONS: 5 rate it Buy, 8 Hold and 2 Sell. The average price target is 92.67.